Vincenzi B - Search Results

1

Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.

Stacchiotti S, Saponara M, Frapolli R, Tortoreto M, Cominetti D, Provenzano S, Negri T, Dagrada GP, Gronchi A, Colombo C, Vincenzi B, Badalamenti G, Zuco V, Renne SL, Collini P, Morosi C, Dei Tos AP, Bello E, Pilotti S, Casali PG, D'Incalci M, Zaffaroni N. Stacchiotti S, et al. Among authors: vincenzi b. Eur J Cancer. 2017 May;76:84-92. doi: 10.1016/j.ejca.2017.02.002. Epub 2017 Mar 8. Eur J Cancer. 2017. PMID: 28284173

2

Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial.

Santini D, Graziano F, Catalano V, Di Seri M, Testa E, Baldelli AM, Giordani P, La Cesa A, Spalletta B, Vincenzi B, Russo A, Caraglia M, Virzi V, Cascinu S, Tonini G. Santini D, et al. Among authors: vincenzi b. BMC Cancer. 2006 May 10;6:125. doi: 10.1186/1471-2407-6-125. BMC Cancer. 2006. PMID: 16686939 Free PMC article. Clinical Trial.

3

Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis.

Russo A, Rizzo S, Fulfaro F, Adamo V, Santini D, Vincenzi B, Gebbia N, Carreca I. Russo A, et al. Among authors: vincenzi b. Cancer. 2009 May 1;115(9):1924-31. doi: 10.1002/cncr.24207. Cancer. 2009. PMID: 19235250 Free article.

4

Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial.

Vincenzi B, Santini D, Russo A, Spoto C, Venditti O, Gasparro S, Rizzo S, Zobel BB, Caricato M, Valeri S, Coppola R, Tonini G. Vincenzi B, et al. Cancer. 2009 Oct 15;115(20):4849-56. doi: 10.1002/cncr.24540. Cancer. 2009. PMID: 19626652 Free article. Clinical Trial.

5

PML down-regulation in soft tissue sarcomas.

Vincenzi B, Perrone G, Santini D, Grosso F, Silletta M, Frezza A, Rossi S, Russo A, Rabitti C, Gebbia N, Badalamenti G, Casali P, Muda AO, Dei Tos AP, Tonini G. Vincenzi B, et al. J Cell Physiol. 2010 Sep;224(3):644-8. doi: 10.1002/jcp.22161. J Cell Physiol. 2010. PMID: 20578240

6

Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network.

Stacchiotti S, Palassini E, Sanfilippo R, Vincenzi B, Arena MG, Bochicchio AM, De Rosa P, Nuzzo A, Turano S, Morosi C, Dei Tos AP, Pilotti S, Casali PG. Stacchiotti S, et al. Among authors: vincenzi b. Ann Oncol. 2012 Feb;23(2):501-8. doi: 10.1093/annonc/mdr066. Epub 2011 Apr 4. Ann Oncol. 2012. PMID: 21464156 Free article.

7

PML expression in soft tissue sarcoma: prognostic and predictive value in alkylating agents/antracycline-based first line therapy.

Vincenzi B, Santini D, Schiavon G, Frezza AM, Silletta M, Crucitti P, Casali P, Dei Tos AP, Rossi S, Rizzo S, Badalamenti G, Tomasino RM, Russo A, Butrynski JE, Tonini G. Vincenzi B, et al. J Cell Physiol. 2012 Apr;227(4):1657-62. doi: 10.1002/jcp.22889. J Cell Physiol. 2012. PMID: 21678421

8

Electroporation adopting trains of biphasic pulses enhances in vitro and in vivo the cytotoxic effect of doxorubicin on multidrug resistant colon adenocarcinoma cells (LoVo).

Meschini S, Condello M, Lista P, Vincenzi B, Baldi A, Citro G, Arancia G, Spugnini EP. Meschini S, et al. Among authors: vincenzi b. Eur J Cancer. 2012 Sep;48(14):2236-43. doi: 10.1016/j.ejca.2011.11.031. Epub 2012 Jan 11. Eur J Cancer. 2012. PMID: 22240284

9

Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience.

Vincenzi B, Silletta M, Schiavon G, Frezza AM, Del Vescovo R, Zobel BB, Santini D, Dei Tos AP, Tonini G. Vincenzi B, et al. Expert Opin Investig Drugs. 2013 Jan;22(1):1-7. doi: 10.1517/13543784.2013.742886. Epub 2012 Nov 16. Expert Opin Investig Drugs. 2013. PMID: 23157681 Clinical Trial.

10

Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients.

Vincenzi B, Zoccoli A, Schiavon G, Iuliani M, Pantano F, Dell'aquila E, Ratta R, Muda AO, Perrone G, Brunelli C, Correale P, Riva E, Russo A, Loupakis F, Falcone A, Santini D, Tonini G. Vincenzi B, et al. Eur J Cancer. 2013 Apr;49(6):1501-8. doi: 10.1016/j.ejca.2012.11.014. Epub 2012 Dec 22. Eur J Cancer. 2013. PMID: 23266047 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

507 results

Search Page

Filters